Skip to main content

Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · IEX Real-Time Price · USD
8.00
-0.10 (-1.24%)
After-hours:Sep 17, 2021 7:59 PM EDT
8.10
2.35 (40.87%)
At close: Sep 17, 4:00 PM
Market Cap641.08M
Revenue (ttm)58.80M
Net Income (ttm)-92.11M
Shares Out79.15M
EPS (ttm)-1.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume66,372,967
Open7.65
Previous Close5.75
Day's Range7.50 - 11.95
52-Week Range3.02 - 11.95
Beta0.12
AnalystsBuy
Price Target6.55 (-19.1%)
Est. Earnings Daten/a

About IPHA

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumo...

IndustryBiotechnology
IPO DateOct 17, 2019
CEOMondher Mahjoubi
Employees244
Stock ExchangeNASDAQ
Ticker SymbolIPHA
Full Company Profile

Financial Performance

In 2020, Innate Pharma's revenue was 70.45 million, a decrease of -17.90% compared to the previous year's 85.81 million. Losses were -63.98 million, 208.2% more than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 5 analysts, the average rating for Innate Pharma stock is "Buy." The 12-month stock price forecast is 6.55, which is a decrease of -19.14% from the latest price.

Price Target
$6.55
(-19.14% downside)
Analyst Consensus: Buy

News

Here's Why Innate Pharma Stock Is Rocketing Higher Today

A clinical trial with an experimental lung cancer drug produced some positive results.

10 hours ago - The Motley Fool

What Is Happening With Innate Pharma Stock On Friday?

Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Onc...

13 hours ago - Benzinga

Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented re...

16 hours ago - GlobeNewsWire

Monalizumab Data From COAST Trial Presented at ESMO Congress 2021

Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented r...

16 hours ago - GlobeNewsWire

Innate Pharma Reports First Half 2021 Financial Results and Business Update

MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six month...

2 days ago - GlobeNewsWire

Innate Pharma reports first half 2021 financial results and business update

Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended ...

2 days ago - GlobeNewsWire

Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update

MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on We...

1 week ago - GlobeNewsWire

Why Innate Pharma Shares Are Rising On Friday?

Innate Pharma SA (NASDAQ:IPHA) stock closed almost 14% higher on Thursday after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress. The presentations include a late...

2 weeks ago - Benzinga

Monalizumab and ANKET™ Data Will be Presented at ESMO 2021 Virtual Congress

Marseille, France, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-break ing abstract on COAST Phase 2 trial

2 weeks ago - GlobeNewsWire

Monalizumab and ANKET™ Data Will Be Presented at ESMO 2021 Virtual Congress

AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial AstraZeneca to present new data on monalizumab in combination with durval...

2 weeks ago - GlobeNewsWire

Innate Pharma to Participate in Upcoming Investor Conferences

MARSEILLE, France, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior mana...

2 weeks ago - GlobeNewsWire

Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints

Innate Pharma SA (NASDAQ: IPHA) has announced its Phase 2 FORCE trial evaluating avdoralimab in COVID-19 patients with severe pneumonia did not meet its primary endpoints in all three cohorts trial. Bas...

2 months ago - Benzinga

Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Investigator-sponsored FORCE trial did not meet primary endpoints

2 months ago - GlobeNewsWire

Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneumonia

Marseille, France, July 06, 2021 (GLOBE NEWSWIRE) -- Investigator-sponsored FORCE trial did not meet primary endpoints

2 months ago - GlobeNewsWire

Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients

Innate Pharma SA (NASDAQ: IPHA) has announced preliminary data from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab. Data were shared at the International ...

2 months ago - Benzinga

Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy

Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™ Company to highlight lacutamab data in mycosis fungoides and share data on...

3 months ago - GlobeNewsWire

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Marseille, France, June 10, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced it will present the latest preclinica...

3 months ago - GlobeNewsWire

New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference...

First clinical data of mycosis fungoides presented from the TELLOMAK trial First clinical data of mycosis fungoides presented from the TELLOMAK trial

3 months ago - GlobeNewsWire

New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference...

First clinical data of mycosis fungoides presented from the TELLOMAK trial First clinical data of mycosis fungoides presented from the TELLOMAK trial

3 months ago - GlobeNewsWire

Outcome of Innate Pharma's Annual General Meeting

MARSEILLE, France, May 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders...

3 months ago - GlobeNewsWire

Innate Pharma Virtual 2021 Annual General Meeting

MARSEILLE, France, May 12, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) has published the convening notice to the Bullet...

4 months ago - GlobeNewsWire

Innate Pharma First Quarter 2021 Report

MARSEILLE, France, May 11, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its revenue and cash position for...

4 months ago - GlobeNewsWire

Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update

MARSEILLE, France, May 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a co...

4 months ago - GlobeNewsWire

Innate Pharma Files its 2020 Universal Registration Document (Document d'Enregistrement Universel) and 2020 Annual Re...

Marseille, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020 Univers...

4 months ago - GlobeNewsWire

Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021

The Annual General Meeting will be broadcasted live by the Company

4 months ago - GlobeNewsWire